Avances en los tumores del estroma gastrointestinal

Delgado, Mercedes; Amate, Alicia Hernández; León, María Sánchez; Gallardo, S. Pereira; González‐Cámpora, Ricardo

doi:10.1016/j.patol.2009.11.003

Cited by 1 publication

(3 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, neoadjuvant therapy with imatinib did not substantially reduce the tumour size, and histologically, we only observed extensive haemorrhagic foci without a decrease in the number of tumour cells or the presence of myxohyaline stroma, necrosis, or cystic degeneration, as previously described in cases that exhibited an initial response to treatment [3]. However, both tumours were completely resected, and after 8 months of postoperative follow-up and adjuvant therapy with imatinib, the patient remains asymptomatic and cancer-free.…”

Section: Discussionsupporting

confidence: 82%

“…The use of imatinib as a neoadjuvant treatment offers the possibility of a partial tumour regression and stabilisation of the disease [9]. In general, the best therapeutic results have been obtained in tumours with KIT mutations in exons 11 (85%) and 9 (45%) [3], although a global response rate of only 40% in inoperable tumours indicates that resection is a non-curative procedure in many cases [17]. …”

Section: Discussionmentioning

confidence: 99%

“…These findings represent an important advance in the clinical management and our understanding of the biology of this tumour [2]. Although the mutations in KIT and PDGFRA represent the basis of GIST oncogenesis, 5-10% of the GIST cases are negative for mutations in KIT [3]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Collision tumour involving a rectal gastrointestinal stromal tumour with invasion of the prostate and a prostatic adenocarcinoma

et al. 2012

View full text Add to dashboard Cite

BackgroundGastrointestinal stromal tumours (GISTs) are the most common primary mesenchymal neoplasia in the gastrointestinal tract, although they represent only a small fraction of total gastrointestinal malignancies in adults (<2%). GISTs can be located at any level of the gastrointestinal tract; the stomach is the most common location (60-70%), in contrast to the rectum, which is most rare (4%). When a GIST invades into the adjacent prostate tissue, it can simulate prostate cancer. In this study, we report on a case comprising the unexpected collision between a rectal GIST tumour and a prostatic adenocarcinoma.FindingsWe describe the complexity of the clinical, endoscopic and radiological diagnosis, of the differential diagnosis based on tumour biopsy, and of the role of neoadjuvant therapy using imatinib prior to surgical treatment.ConclusionsAlthough isolated cases of coexisting GISTs and prostatic adenocarcinomas have previously been described, this is the first reported case in the medical literature of a collision tumour involving a rectal GIST and prostatic adenocarcinoma components.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1238437468776331.

show abstract

Section: Discussionsupporting

confidence: 82%